Presented by

In collaboration with

November 10-11 | In-Person & Digital (London)

GLOBAL PHARMA AND BIOTECH SUMMIT

REGISTER NOW

Save 10% as an Endpoints reader with code EP10

The US boom in telehealth, online prescribing and self-pay has opened a new way to sell and access medicines. Obesity drugs are the clearest test yet of whether that's a shift or an exception.

For drugmakers, the questions are piling up. How does the model translate to Europe, and to public systems like the NHS? What happens to adherence and trust when treatment starts through retail or digital routes? And how do regulators prevent consumer harm without closing off new channels?

The Global Pharma and Biotech Summit, presented by the Financial Times in collaboration with Endpoints News, puts those questions to the people navigating them. Among the speakers: Hong Chow, executive vice president of product and portfolio strategy at Novo Nordisk. Sessions cover redesigning the patient journey and whether obesity drugs, telehealth and self-pay point to a new access model for Europe. The summit maps how patient behavior is rewriting commercial strategy. Join us in London or online, and see where the access model goes next.